Abeona Congratulates Ultragenyx on FAYUVI FDA Approval
CLEVELAND, Ohio — September 18, 2026 Abeona Therapeutics congratulated Ultragenyx Pharmaceutical on the U.S. FDA approval of FAYUVI™ (rebisufligene...
MPS IIIA
Advertisement
Andelyn Biosciences Advances Commercial Gene Therapy Manufacturing
Columbus, Ohio, September 18, 2026 Andelyn Biosciences has announced a major milestone in commercial gene therapy manufacturing following the...
Ultragenyx Wins FDA Approval for FAYUVI Gene Therapy
Novato, California, U.S., September 17, 2026 Ultragenyx Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has...
Ultragenyx Advances UX111 Gene Therapy Toward Approval
NOVATO, Calif., April 2, 2026 Ultragenyx Pharmaceutical Inc. has reached a significant regulatory milestone as the U.S. Food and...
Ultragenyx Gene Therapy Shows Durable Gains in MPS IIIA
NOVATO, Calif., February 3, 2026 — Ultragenyx Pharmaceutical Inc. has reported positive long-term clinical data for UX111, an investigational...
Advertisement
